Tuberous Sclerosis With Renal AML

28
TUBEROUS SCLEROSIS COMPLEX Ahmed Abdul Ghany

description

 

Transcript of Tuberous Sclerosis With Renal AML

Page 1: Tuberous Sclerosis With Renal AML

TUBEROUS SCLEROSIS COMPLEX

Ahmed Abdul Ghany

Page 2: Tuberous Sclerosis With Renal AML

INTRODUCTION:TSC is an inherited neuro-cutaneous disorder characterized by multiple benign hamartomas of the skin, eyes, brain, heart, lung, kidney and liver.

In 1862 von Recklinghausen identified heart and brain tumors in a newborn that had only briefly lived. However, Bourneville (1880) is credited with having first characterized the disease, thus earning the eponym Bourneville's disease.

Page 3: Tuberous Sclerosis With Renal AML

GENETICS• Autosomal dominant with

incidence 1 in 5000 live births.• Mutation in TSC-1 or TSC-2

genes.• +ve family history in 7 – 37%

Page 4: Tuberous Sclerosis With Renal AML

Diagnostic criteria

Possible TSC

1 major 2 or more minor

Probable TSC1 major plus 1 minor

Definite TSC2 major 1 major + 2 minor

Page 5: Tuberous Sclerosis With Renal AML

DERMATOLOGICAL LESIONS:81-95%

Page 6: Tuberous Sclerosis With Renal AML

Angiofibromas Fibrous plaque

Page 7: Tuberous Sclerosis With Renal AML

Ash leaf spots Periungual & subangual fibromas

Page 8: Tuberous Sclerosis With Renal AML

BRAIN LESIONS90%

Page 9: Tuberous Sclerosis With Renal AML

Glioneuronal hamartomas Subependymal nodules

Page 10: Tuberous Sclerosis With Renal AML

SGCA

Page 11: Tuberous Sclerosis With Renal AML

Clinically (CNS):• Epilepsy affecting 80 – 90% of patients in the form of infantile

spasms, simple or complex partial seizures with EEG +ve in 75 % of patients.

• Cognitive deficits 44 – 65%.

• Autism and behavioral problems.

Page 12: Tuberous Sclerosis With Renal AML

Diagnostic features

associated with increase morbidity

New symptom

s or papillede

ma

Hydrocephalus

Serial imaging showing growth of

lesions

Page 13: Tuberous Sclerosis With Renal AML

RENAL MANIFESTATIONS

Page 14: Tuberous Sclerosis With Renal AML

Renal Angiomyolipomas (AML)

• Common in TSC patients

Page 15: Tuberous Sclerosis With Renal AML

• Asymptomatic in most cases however symptoms may be related to bleeding or mass effect.

• 2 histological types: classic and Epithelioid AML

• Diagnosis relies on the demonstration of Fat in the Tumor

Page 16: Tuberous Sclerosis With Renal AML
Page 17: Tuberous Sclerosis With Renal AML

Prophylactic surgery?

• size ≥4cm to prevent bleeding

• High vascularity and/or aneurysm ≥ 5mm.

• High suspicion of malignancy

Therapeutic interventions

• Nephron sparing surgery

• Selective renal artery embolization

• Radiofrequency ablation

• Radical nephrectomy.

Page 18: Tuberous Sclerosis With Renal AML

Potential issues in women• Female sex hormones promote growth of renal AMLs and

their hemorrhagic complications during pregnancy, thus frequency of US surveillance should increase.

Page 19: Tuberous Sclerosis With Renal AML

Renal cystic disease• The 2nd most common renal manifestation in TSC.

• 3 types of renal cysts are associated:• Singe or multiple renal cysts

• TSC2/PKD1 contiguous gene syndrome• Glomerulocytic kidney disease.

Page 20: Tuberous Sclerosis With Renal AML

Chronic kidney disease:• Some TSC patients may develop CKD, subnephrotic

proteinuria, hypertension and ESRD in absence of large AML.

• Renal biopsy often reveals FSGS.

Page 21: Tuberous Sclerosis With Renal AML

OPHTHALMIC MANIFISTATIONS

Page 22: Tuberous Sclerosis With Renal AML

• Retinal hamartomas• Angiofibromas of the eyelid

Page 23: Tuberous Sclerosis With Renal AML

CARDIOPULMONARY

Page 24: Tuberous Sclerosis With Renal AML

Cardiac (Rhabdomyoma)

• Often detected on prenatal US• Benign tumor usually undergo

spontaneous regression.

Pulmonary (LAM)

• Lymphangioleiomyomatosis• Manifestations are similar to

those with interstital lung disease.

Page 25: Tuberous Sclerosis With Renal AML

Management Everolimus

Pulmonary

cosmetic

Renal AML

Seizure control

Page 26: Tuberous Sclerosis With Renal AML

EVEROLIMUS• FDA approved mTOR inhibitor (ExIST-2 trial)• 50% reduction in AML volume in 3 month• Recommended dose: 10 mg od for 38 weeks• Reasonable candidates are:

• patients with renal AML plus other organ affected• Rapidly growing AMLs.

• Patients who underwent nephrectomy or embolization.

Page 27: Tuberous Sclerosis With Renal AML

Prognosis • TSC is a progressive disorder.

• Causes of death usually due to status epilepticus or renal disease.

• Surveillance is recommended every 2 years including mental, physical examination, MRI brain, US and ECHO.

Page 28: Tuberous Sclerosis With Renal AML

THANK YOU